Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC)

Lori Wirth, MD, moderates a panel of medical experts specializing in radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), discussing current treatments and ongoing clinical trials in this field.

EP. 1: Differentiated Thyroid Cancer: Examining Key Epidemiological Trends

March 22nd 2024

Medical experts provide an overview of differentiated thyroid cancer, highlighting key epidemiological trends, and discuss the impact of thyroid cancer in women.

EP. 2: Exploring Incidence and Histology of Differentiated Thyroid Cancer

March 22nd 2024

Marcia Brose, MD, delivers a comprehensive overview of differentiated thyroid cancer, detailing the incidence rates, histological features, genetic profiles, and phenotypic characteristics associated with this malignancy, providing valuable insights into the complex nature of the disease.

EP. 3: Determining Prognosis for Patients with Differentiated Thyroid Cancer

March 29th 2024

Francis Worden, MD, discusses the prognosis for patients with differentiated thyroid cancer, distinguishing between those who can be put on close surveillance and those who require immediate treatment, while the panel weighs in on best practices for predicting and anticipating disease-related obstructions prior to the onset of symptoms.

EP. 4: Predisposition for Patients Developing DTC: Age and Gender

March 29th 2024

The panel explores potential reasons for the higher incidence of thyroid cancer diagnoses in women compared to men, while also discussing diagnosis in the pediatric population and examining the influence of environmental and genetic factors on detection bias.

EP. 5: The Role of Molecular Diagnostics in Real-World DTC Management

April 5th 2024

Daniel Bowles, MD, explores the role of molecular testing in driving treatment decisions and its application in the initial diagnosis stage, while also discussing driver mutations, primary surgeries, and the importance of high-quality DNA and RNA, highlighting the 2-year window for durable RNA sequencing.

EP. 6: Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

April 5th 2024

Francis Worden, MD, and Hyunseok Kang, MD, express caution regarding the use of liquid biopsies due to discordant findings and the potential lack of tumor shedding compared to other solid tumors, while also warning about the misinterpretation of Clonal hematopoiesis of indeterminate potential mutations.

EP. 7: The Importance of Thyroidectomy in DTC Patient Care

April 12th 2024

Medical professionals discuss the role of thyroidectomy and nodal disease in leading to surgery, providing an overview of the various surgical treatment options available for differentiated thyroid cancer.

EP. 8: Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression

April 12th 2024

The panel discusses the importance of thyroid hormone replacement and TSH suppression, highlighting the role of endocrinologists in managing the risk of cardiovascular disease. Dr. Brose also addresses the potential long-term risks associated with radioactive iodine treatment in the post-surgery setting, including cytopenia, salivary gland issues, and excessive tearing of the eyes.

EP. 9: Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

April 19th 2024

Daniel Bowles, MD, leads a discussion on radioactive iodine (RAI) refractory disease, exploring the incidence and resistance levels, and provides recommendations for identifying patient populations who are ineligible for radioiodine treatment.

EP. 10: SELECT Trial & DECISION Trial Outcomes and Lessons Learned

April 19th 2024

Francis Worden, MD, analyzes the outcomes of the SELECT and DECISION Trials, focusing on progression-free survival, and provides recommendations for their application in clinical practice.

EP. 11: Determining Which DTC Patients May Benefit from Systemic Therapy

April 26th 2024

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.